The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
Open accessAbstract
The mutant form of the guanosine triphosphatase (GTPase) KRAS is a key driver in human tumors but remains a challenging therapeutic target, making KRAS MUT cancers a highly unmet clinical need. Here, we report a class of bottlebrush polyethylene glycol (PEG)–conjugated antisense oligonucleotides (ASOs) for potent in vivo KRAS depletion. Owing to their highly branched architecture, these molecular nanoconstructs suppress nearly all side effects associated with DNA–protein interactions and substantially enhance the pharmacological properties of the ASO, such as plasma pharmacokinetics and tumor uptake. Systemic delivery to mice bearing human non–small-cell lung carcinoma xenografts results in a significant reduction in both KRAS levels and tumor growth, and the antitumor performance well exceeds that of current popular ASO paradigms, such as chemically modified oligonucleotides and PEGylation using linear or slightly branched PEG. Importantly, these conjugates relax the requirement on the ASO chemistry, allowing unmodified, natural phosphodiester ASOs to achieve efficacy comparable to that of chemically modified ones. Both the bottlebrush polymer and its ASO conjugates appear to be safe and well tolerated in mice. Together, these data indicate that the molecular brush–ASO conjugate is a promising therapeutic platform for the treatment of KRAS -driven human cancers and warrant further preclinical and clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additional emerging modalities include RNA-targeted therapeutics, antisense oligonucleotides, siRNA-based suppression [65,66], neoantigen vaccines [67,68], and adoptive T-cell therapies targeting mutant KRAS-derived epitopes [69,70].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular dynamics with coupling to an external bath
Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984) · The Journal of Chemical Physics · doi:10.1063/1.448118 · Cited by 30,700 · cited 1×
“The temperature was controlled at 310 K using the Berendsen thermostat while the pressure was controlled at 1 atm using the Berendsen barostat (57).”
MethodGROMACS: Fast, flexible, and free
Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. C. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20291 · Cited by 19,182
The MARTINI Force Field: Coarse Grained Model for Biomolecular Simulations
Marrink, S. J., Risselada, H. J., Yefimov, S., Tieleman, D. P., & de Vries, A. H. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp071097f · Cited by 5,562
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 1×
“Importantly, the observed physiochemical and biopharmaceutical enhancements over naked nucleic acids are realized using predominantly PEG, which is generally regarded as safe for therapeutic applications (37).”
BackgroundExosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · cited 1×
“The difficulty in developing small-molecule inhibitors for KRAS has heightened the importance of alternative methods targeting the oncogene, for example using antisense oligonucleotides (ASOs) (10), which offer a possibility to yield drugs for targets that have proven to be intractable to traditional drug modalities (…”
BackgroundK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“However, in 2013, it was shown that the cysteine residue of the G12C mutant give rise to a new pocket that can be selectively targeted by small-molecule binders (3, 7).”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationAdvances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“The missense mutation of KRAS aberrantly activates the protein into a hyperexcitable state by attenuating its guanosine triphosphatase (GTPase) activity, which results in an accretion of GTP-bound, activated KRAS and persistent activation of downstream signaling pathways (2).”
Background
Cited by
Chemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 172
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 79
Lu, J., Dai, Y., He, Y., Zhang, T., Zhang, J., Chen, X., Jiang, C., & Lu, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11914 · Cited by 51
New prospectives on treatment opportunities in RASopathies
Gelb, B. D., Yohe, M. E., Wolf, C. M., & Andelfinger, G. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32024 · Cited by 42
Xue, L., Xiong, X., Zhao, G., Arocho, W. A. M., Palanki, R., Xiao, Z., Han, X., Yoon, I., Figueroa‐Espada, C. G., Xu, J., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c10265 · Cited by 43
Metadata
- Authors
- Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., He, J., Lian, L., Morano, G., Shen, M., Ren, M., Dong, S. S., Zhao, J. J., & Zhang, K.
- Affiliations
- Northeastern University (US)
- Harvard University (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Corresponding author
- Zhao, Jean J.
- Zhang, Ke
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2022-07-14
- Volume
- 119
- Issue
- 29
- Pages
- e2113180119-e2113180119
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC9304022
- OpenAlex
- W4285387133
- Cited by
- 43
- References
- 57
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 12 · 2023: 5 · 2022: 6
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (1R01CA251730)
- HHS | NIH | National Institute of General Medical Sciences (1R01GM121612)
- National Science Foundation (2004947)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- KRAS mutation, antisense oligonucleotides, bottlebrush polymers, molecular brushes, non-small cell lung cancer, pharmacokinetics, tumor uptake, antitumor efficacy, drug delivery
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Polyethylene Glycols, Proto-Oncogene Proteins p21(ras), Oligonucleotides, Antisense, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. https://app.cochat.ai/papers/10.1073/pnas.2113180119
- The paper
- Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., He, J., Lian, L., Morano, G., Shen, M., Ren, M., Dong, S. S., Zhao, J. J., & Zhang, K. (2022). Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2113180119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.